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Objective: Synovitis associated with osteoarthritis (OA) is directly responsible for several clinical
symptoms and reﬂects OA's structural progression. This study sought to analyze the expression of
proinﬂammatory mediations, including Interleukin (IL)-17 and IL-22, which play key roles in regulating
inﬂammatory processes, in inﬂamed and non-inﬂamed areas of osteoarthritic synovium.
Methods: Synovium from knees of 32 OA patients were collected at surgery. Macroscopic evaluation of
inﬂammation enabled inﬂamed and non-inﬂamed areas to be separated. Samples were incubated to
obtain tissue-conditioned media. Quantitative mRNA expression of proinﬂammatory mediators was
analyzed by RT-PCR and protein levels by ELISA and gelatin zymography. Immunohistochemistry and
histology were performed.
Results: Inﬂamed synovium were characterized by increased leukocyte inﬁltration and a higher vessel-
to-tissue area ratio than non-inﬂamed tissues. Macrophages, T and B lymphocytes, and some neutro-
phils were found only in the inﬂamed tissue, and only in the subintimal layer. Levels of proinﬂammatory
cytokines and MMP-9 were signiﬁcantly higher in tissue-conditioned media from inﬂamed than non-
inﬂamed tissues. Inﬂamed areas were associated with higher expression of IL-17 and IL-22, both
correlated with the combined release of IL-6, IL-23, and TGFb1.
Conclusion: Our results showed that inﬂammatory cytokines, including IL-17 and IL-22, are expressed at
higher levels by inﬂamed OA synovium and suggest IL-22 involvement in OA pathophysiology. This study
will help identify new therapeutic strategies for OA, especially the targeting of IL-22 to decrease
inﬂammation.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
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lf of Osteoarthritis Research Societbreakdown, the formation of bony outgrowths at joint margins
(osteophytes), subchondral bone sclerosis, impairments of the joint
capsule and inﬂammation of the synovium1,2. The latter results in
synovitis, which is directly responsible for several clinical symp-
toms and mirrors OA's structural progression. Hence treatments
that speciﬁcally target this previously neglected component of OA
could help to prevent or reduce both the symptoms and structural
changes of OA. Synovitis in OA is not uniform and diffuse, but ap-
pears to be anatomically restricted and to vary in intensity3. Neither
OA's etiology nor its pathophysiology is well understood, but it is
believed that secreted inﬂammatory molecules (such as proin-
ﬂammatory cytokines) are among the critical mediators of the
pathophysiological processes. Nonetheless, the differential releasey International.
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as deﬁned by histological characteristics, has never been investi-
gated, although Lambert et al. recently showed the differential
mRNA expression of several inﬂammatory cytokines by cultures of
ﬁbroblast-like synoviocytes (FLS) isolated from inﬂamed and
normal/reactive OA synovium4.
Interleukin (IL)-1b and tumor necrosis factor (TNF)-a are two
major cytokines known to be involved in OA pathogenesis. Both can
also stimulate chondrocytes and synovial cells to produce other
potent proinﬂammatory cytokines, including IL-6 and IL-8, as well
as matrix metalloproteinases (MMPs) and prostaglandin E25. All of
these are thought to diffuse into the synovial ﬂuid and act on the
cartilage matrix and chondrocytes.
IL-17, produced mainly by IL-17-secreting CD4þ cells (called
Th17), is also reported to be closely associated with OA patho-
genesis6e12. IL-17 is deﬁned by its ability to induce the expression of
proinﬂammatory cytokines and inﬂammatory chemokines and is a
critical mediator in neutrophil recruitment, migration and
activation.
IL-22 is secreted mainly by Th17 cells, but also by special im-
mune cell populations, including Th22, Th1, classical and non-
classical (NK-22) NK cells, NKT cells, and lymphoid tissue inducer
cells13. IL-22 belongs to the IL-10 superfamily of cytokines and
signals through a heterodimeric receptor complex composed of the
IL-22R1 and IL-10R2 chains14. Unlike the IL-10R2 chain, which is
ubiquitous, IL-22R1 is expressed only by non-immune cells13,
including joint FLS15. The main biological functions of IL-22 are to
increase innate immunity, protect against damage, and enhance
regeneration16e19. The role of IL-22 in inﬂammatory disorders is
still controversial, and both protective and highly pathogenicFig. 1. Macroscopic and histological evaluation of inﬂamed and non-inﬂamed synovium from
(AT) (a and e). Inﬂamed (Inﬂ) and non-inﬂamed tissues (NI) are from the same synovium. T
are characterized by the presence of hypertrophic and hyperemic villi (e). Immunohistochem
cells (CD31) (b and f) and leukocytes (CD45) (c and g). The red dashed line separates the intim
tissues due to increased cellularity. Vessels (arrows) are present in the subintimal layer of syn
non-inﬂamed synovium (c). They are found as isolated cells (thin arrows) in the intimal and s
of foci of CD45-positive inﬁltrates (asterisk) in addition to isolated cells (thin arrows) (g). Pa
tissue area (B) and of the leukocyte inﬁltrate (C) in inﬂamed and non-inﬂamed OA synovium
Data are expressed as mean ± SD. D) The ratio of vessel-to-tissue area is strongly and posifunctions have been described20,22,23. Constitutive expression of IL-
22 in FLS from OA patients has recently been reported21.
The aim of our study was thus to analyze the differential
expression of IL-22 in inﬂamed and non-inﬂamed areas of syno-
vium from OA patients. At the same time, we evaluated the
expression of IL-17 and various other proinﬂammatory cytokines,
especially those involved in the emergence of IL-22þ cells (IL-1b, IL-
6, IL-18, IL-23 and TGF-b1) and MMPs. We also investigated asso-
ciations between these indicators and the histological grade of the
corresponding inﬂammatory processes.
Material and methods
Materials
Human osteoarthritic knee samples (n ¼ 32) were obtained
from the orthopedics department of Saint-Antoine Hospital, Paris,
as surgical waste. Informed consent was obtained before surgery.
Experiments using human samples have been approved by a French
Institutional Review Board (Comite de Protection des Personnes Ile
de France V). The investigation complied with the principles out-
lined in the Declaration of Helsinki. Patients (75.8% of women)were
70.3 ± 9.8 years (range 54e88). Inﬂamed areas of the synovium
were isolated from adjacent non-inﬂamed areas after macroscopic
evaluation of inﬂammation, deﬁned as hypervascularized areas
with hypertrophic and hyperemic villi [Fig.1(A), (a) and (e)]4,22. The
remaining synovial tissue was considered non-inﬂamed. Synovium
from both types of areas was cut into small pieces (~1 mm3) and
incubated (6 mL/mg wet tissue) for 24 h at 37C in RPMI-1640
culture medium containing 1% L-glutamine, 1% penicillin, andOA patients A) Macroscopic views of OA synovium (S) and its adjacent adipose tissue
he dashed line separates the synovium (S) from the adipose tissue (AT). Inﬂamed areas
ical analysis of inﬂamed and non-inﬂamed OA synovium (n ¼ 9) to identify endothelial
al from subintimal part of the synovium. Note the thickening of the intima in inﬂamed
ovium (b and f). Vessels are larger in inﬂamed areas (f). Few leukocytes are observed in
ubintimal layers. Inﬂammatory areas of OA synovium are characterized by the presence
nels d and h: negative controls. Bar ¼ 200 mm. Quantiﬁcation of the ratio of vessel-to-
(n ¼ 9). Inﬂamed areas have signiﬁcantly greater vessel area and leukocyte inﬁltrates.
tively correlated with the leukocyte inﬁltrate.
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of the incubation period, tissue samples were stored at 80C and
tissue-conditionedmedium samples were centrifuged at 3000 g for
5 min. Aliquots of supernatant were stored at 80C. Fresh tissue
samples for gene expression analysis were immediately frozen in
liquid nitrogen after dissection and stored at 80C until RNA
extraction.
Histology and immunohistochemistry
Pieces of the inﬂamed and the non-inﬂamed area of each
synovium sample (n ¼ 20) were ﬁxed for 48 h in 3.7% para-
formaldehyde at 4C. Samples were embedded in parafﬁn and
serially sectioned (5 mm). Tissue morphology was evaluated by
hematoxylineeosin staining. Immunohistochemistry was per-
formedwithmousemonoclonal antibodies (mAb) to CD31 (PECAM,
JC70A, Dako), CD45 (leukocytes, clone 2B11þPD7/26, Dako), CD3 (T
lymphocytes, clone F7.2.38, Dako), CD15 (neutrophils, clone H198,
eBiosciences), CD20 (B-lymphocytes, clone L26, Dako) and CD68
(macrophages, clone PG-M1, Dako) as primary antibodies and a
peroxidase Dako LSABþ kit for detection. Irrelevant control anti-
bodies (Dako) were applied at the same concentration to assess
non-speciﬁc staining. Sections were counterstained with Mayer's
hematoxylin.
Morphometric analysis
After the endothelial cells were immunostained with anti-CD31
mAb and the areas quantiﬁed with MultiGauge V3.O software
(Fujiﬁlm), the ratio of vessel-to-tissue area was calculated. Leuko-
cyte inﬁltrates were quantiﬁed on slices immunostained with anti-
CD45 mAb. Each cluster of 4e5 CD45-positive cells was numbered.
Synovium were histologically graded according to the scale estab-
lished by Haywood et al.24: 0 ¼ normal (synovial lining < 4 cells
thick, sparse cellular distribution, with few or no inﬂammatory
cells), 1¼mild inﬂammation (synovial lining four or ﬁve cells thick,
increased cellularity with some inﬂammatory cells), 2 ¼ moderate
inﬂammation (synovial lining six or seven cells thick, dense cellu-
larity with inﬂammatory cells but no lymphoid aggregates),
3 ¼ severe inﬂammation (synovial lining > 7 cells thick, dense
cellularity and inﬂammatory cell inﬁltration, may contain peri-
vascular lymphoid aggregates).
Zymography
Gelatin zymography was performed as previously described25.
Samples were loaded onto 8% SDS/PAGE gels containing bovine skin
gelatin (1.2mg/mL). After electrophoresis, SDSwas removed by two
1-h washes in 12.5 mM Tris/HCl, pH 7.4, 2.5% Triton X-100, followed
by one 30-min wash in a buffer containing 50 mM Tris/HCl, pH 7.4,
100 mM NaCl, and 5 mM CaCl2. The washed samples were then
incubated overnight at 37C in the same buffer. Lysis bands were
revealed by Coomassie brilliant blue R-250 staining. Gelatinase
activity was quantiﬁed by densitometry with MultiGauge V3.O
software (Fujiﬁlm).
Measurement of cytokine levels in synovial membrane-conditioned
media
Biochemical analysis of synovium-conditioned media for the
known proinﬂammatory mediators was performed with commer-
cially available enzyme-linked immunosorbent assay (ELISA kits)
[MPO (Hycult); IL-1b, IL-6, IL-8 and TNF-a (Sankin Pelikine); IL-17,
IL-22 and IL-23 (eBiosciences); IL-18 (MBL) and TGFb1 (R&D
Systems)].RNA extraction, reverse transcription and real-time quantitative PCR
Total RNA was extracted with the RNeasy mini kit (Qiagen,
Courtaboeuf, France), including a DNase digestion step (RNasefree
DNase set, Qiagen), according to the manufacturer's instructions.
Total RNA (0.3e1 mg) was reverse-transcribed with the Omniscript
kit (Qiagen) in a ﬁnal volume of 20 mL containing 50 ng of oligodT;
cDNA was quantiﬁed by real-time quantitative PCR (RT-PCR) with
LC480 Light Cycler Real Time PCR (Roche Diagnostics, Meylan,
France). PCR reactions were performed with Go Taq qPCR Master
Mix (Promega, Charbonnieres-les-Bains, France), under the
following PCR ampliﬁcation conditions: initial denaturation for
5min at 95C followed by 40 cycles consisting of 10 s at 95C,15 s at
60C and 10 s at 72C. Product formationwas detected at 72C in the
ﬂuorescein isothiocyanate channel. The generation of speciﬁc PCR
products was conﬁrmed by melting-curve analysis. For each PCR,
cDNAs were run simultaneously in duplicate with serial dilutions of
a cDNA mixture tested for each primer pair to generate a standard
linear curve, which was used to estimate ampliﬁcation efﬁciency.
Relative quantities of each mRNA of interest, normalized to those of
GAPDH used as internal reference gene, were determined by the E-
method (efﬁciency) method of LightCycler 480 software.
The following speciﬁc oligonucleotide primers were used: IL-
17A, sense 50CCTATAAGCAAAACAAAGCATGTC30 and anti-sense
50CGAGAACTTGGAATTTTGGGTA30; IL-22, sense 50TTCTCTTGG
CCCTCTTGGTA30 and anti-sense 50GCTGCTGGAAGTTGGACTTG30
and human GAPDH, sense 50CCATCACCATCTTCCA30 and anti-sense
50CCTTCTCCATGGTGGT30.
Statistical analysis
Paired Wilcoxon non-parametric tests (Statview software,
version 4.57) were used to compare the results for inﬂamed and
non-inﬂamed OA synovium from the same sample. Correlations
were established with Spearman's rank test. Statistical signiﬁcance
was deﬁned as P < 0.05.
Results
Histological evaluation of inﬂamed and non-inﬂamed OA synovium
Macroscopic evaluation of osteoarthritic synovium showed tis-
sue heterogeneity, with inﬂammatory areas characterized by
hypervascularized areas containing hypertrophic and hyperemic
villi, and adjacent areas showing no apparent signs of inﬂammation
[Fig. 1(A), (a) and (e)]. Consistent with the description by Ayral
et al.22, the non-inﬂamed areas appeared reactive with a prolifer-
ation of opaque villi of normal morphology or somewhat more
thick and squat. Loss of translucency prevented visualization of the
vascular network22. Non-inﬂamed areas could also show a normal
appearance, with few translucent and slender villi22, although they
originated from diseased tissues.
Microvessels were localized in the subintimal layer of synovium
as revealed by CD31-positive immunostaining [Fig. 1(A), (b) and
(f)]. In inﬂamed areas, microvessels appeared larger than those
found in non-inﬂamed areas. This result was conﬁrmed by the
quantiﬁcation of the area occupied by vessels [Fig. 1(B)]. A 2.4-fold
increase in vessel area/tissue area was measured in inﬂamed as
compared to non-inﬂamed areas (P ¼ 0.009), consistent with the
hyperemic appearance of inﬂamed synovium.
The histological changes that occurred in inﬂamed areas also
included hypertrophy and hyperplasia, with an increase in the
number of cells lining the synovium. These changes were accom-
panied by the inﬁltration of scattered foci of leukocytes (CD45þ
cells) in the subintimal layer [Fig. 1(A), (g)]. The number of
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non-inﬂamed tissues (P ¼ 0.001) [Fig. 1(C)]. Leukocyte inﬁltration
and the ratio of the vessel-to-tissue area were positively correlated
(r ¼ 0.726, P ¼ 0.006) [Fig. 1(D)]; this ﬁnding underlines that their
hyperemic appearance distinguishes inﬂamed OA synovium from
non-inﬂamed tissues.
In inﬂamed tissues, leukocytes preferentially accumulated
within the subintimal layer [Fig. 1(A), (g)]. In particular, we
observed aggregates of T (CD3þ) and B (CD20þ) lymphocytes and
macrophages (CD68þ cells) [Fig. 2(e)e(g)]. Some neutrophils
(CD15þ cells) were also detected [Fig. 2(h)]. In contrast, in the non-
inﬂamed areas, leukocytes were localized in the intimal layer
[Fig. 1(A), (c)] and were exclusively represented bymacrophages, as
revealed by CD68-positive immunostaining [Fig. 2(a)]. However,
CD68-positive immunostaining was weaker in non-inﬂamed
compared with inﬂamed synovium [Fig. 2(a) and (e)]. We did not
observe the presence of either neutrophils or T or B lymphocytes
[Fig. 2(b)e(d)].
Higher release of myeloperoxidase (MPO) and MMP-9 by inﬂamed
osteoarthritic synovium
We next sought to characterize the biochemical features cor-
responding to these histological ﬁndings, by assessing twomarkers
of inﬂammation d MPO and MMP-9 d in inﬂamed and non-
inﬂamed OA synovium. MPO was detected in tissue-conditioned
media from both types of tissues [Fig. 3(A)], but signiﬁcantly
higher levels were released by the inﬂamed ones [Fig. 3(A)]. Simi-
larly, MMP-9 was barely detectable in media conditioned by non-
inﬂamed media, but was found at much higher levels in the me-
dia conditioned by inﬂamed tissue [Fig. 3(B) and (C)]. In contrast,
MMP-2, which is expressed constitutively, was found at similar
levels in both types of media [Fig. 3(B)].
Interestingly, the levels of both MPO and MMP-9 released by
synovium correlated positively with the inﬂammation grade, ac-
cording to the histological scale established by Haywood et al.24
(r ¼ 0.459, P ¼ 0.031 for MPO and r ¼ 0.614, P ¼ 0.007 for MMP-Fig. 2. Histological characterization of leukocyte inﬁltration in inﬂamed and non-inﬂamed
(n ¼ 5e12) (el) were stained for CD68 macrophages (a and e), CD3 T-lymphocytes (b and
antibodies as negative controls (i-l). CD68-positive staining is observed in the intima of no
localized both in the intima, where staining is stronger than in the non-inﬂamed areas,
lymphocytes (c) and no neutrophils (d). The leukocyte inﬁltrate of the subintima of inﬂam
inﬂamed synovium, some CD15 neutrophils (arrows) can be observed in the subintima
magniﬁcation view of the delimited area showing a neutrophil with its typical polylobular9) [Fig. 3(D) and (E)]. That is, the biochemical ﬁndings conﬁrmed
the histological data: higher quantities of inﬂammatory markers
were released by inﬂamed comparedwith non-inﬂamed synovium.
Expression of classical pro- and anti-inﬂammatory cytokines in
inﬂamed and non-inﬂamed OA synovium
We next analyzed tissue-conditioned media from inﬂamed and
non-inﬂamed synovium from each sample to determine whether
either set released speciﬁc cytokines. IL-1b, IL-6, IL-8, IL-18, IL-23,
TGFb1 and RANTES were detected in synovium-conditioned media
[Figs. 4 and 5]. The level of TNF-a was at the limit of detection, and
IL-12p70 was not detected (data not shown). Concentrations of IL-
1b, IL-6, IL-8, IL-18 and TGFb1 were signiﬁcantly higher in media
conditioned by inﬂamed, compared with non-inﬂamed, tissues
(Fig. 4). In contrast, similar amounts of IL-23 [Fig. 4(E)] and RANTES
(data not shown) were released by both types.
The strong and positive correlations between IL-1b, IL-6, IL-8, IL-
18 and IL-23 levels and TGFb1 levels in tissue-conditionedmedia by
inﬂamed and non-inﬂamed OA tissues analyzed together provided
further evidence of the inﬂammatory potency of OA synovium
(Supplemental Table). Moreover, the concentration of MPO in
conditioned media correlated with the levels of several cytokines
released by OA synovial tissues, including IL-8, IL-18, IL-23 and
TGFb1 (Supplemental Table), while MMP-9 levels were associated
with IL-1b and IL-6 concentrations (r ¼ 0.370, P ¼ 0.038 for IL-1b
and r ¼ 0.380, P ¼ 0.037, for IL-6). In addition, the release of each of
IL-1b, IL-6, IL-8, IL-18, IL-23 and TGFb1 by OA synovium was asso-
ciated with the synovial inﬂammation grade (IL-1b, r ¼ 0.671,
P ¼ 0.003; IL-6, r ¼ 0.439, P ¼ 0.05; IL-8 r ¼ 0.481, P ¼ 0.035; IL-18,
r ¼ 0.448, P ¼ 0.035; IL-23, r ¼ 0.538, P ¼ 0.016; and TGFb1,
r ¼ 0.556, P ¼ 0.015) (Fig. 5).
Higher release of IL-17 and IL-22 by inﬂamed OA synovium
As IL-17 and IL-22 play key roles in the regulation of inﬂam-
matory processes, we next investigated their expression andOA synovium. Parafﬁn sections (5 mm) of non-inﬂamed (aed) and inﬂamed tissues
f) and CD20 B-lymphocytes (c and g), CD15 neutrophils (d and h) or with irrelevant
n-inﬂamed tissues (a). In the inﬂamed areas of these OA synovium, macrophages are
and in the subintimal space (arrows) (e). Non-inﬂamed synovium contain no T or B
ed synovium also contains T (f) and B lymphocytes (g), organized in clusters. In the
where they are found within leukocyte inﬁltrates and vessels (h). (h, inset) Higher
nuclei. Bars ¼ 200 mm.
Fig. 3. Biochemical evaluation of inﬂamed and non-inﬂamed synovium of OA patients. Conditioned media from inﬂamed and non-inﬂamed areas of OA synovium were tested for
MPO (n ¼ 20) (A) and gelatinases (n ¼ 16) (B) by ELISA and gelatin zymography, respectively. A) A signiﬁcantly higher level of MPO was released by inﬂamed areas of OA synovium,
compared to adjacent non-inﬂamed areas. B) Representative activity of gelatinase released by inﬂamed and non-inﬂamed areas of synovium from two patients. Gelatin zymography
allowed detection of two principal gelatinases: MMP-2 and MMP-9. No difference in MMP-2 activity was observed between the inﬂamed and non-inﬂamed areas. In contrast, MMP-
9 activity appeared stronger in media conditioned by inﬂamed areas. C) Densitometric analysis of MMP-9 activity revealed by gelatin zymography. Signiﬁcantly higher MMP-9
activity was detected in media conditioned by inﬂamed, compared with non-inﬂamed, areas. D and E) Positive associations between the release of MPO and MMP-9 by OA
synovium and the tissue inﬂammation grade of inﬂamed and non-inﬂamed areas (n ¼ 21 and n ¼ 19, for MPO and MMP-9, respectively).
Fig. 4. Differential release of cytokines by inﬂamed and non-inﬂamed synovium from OA patients. Levels of IL-1b (n ¼ 19) (A), IL-6 (n ¼ 17) (B), IL-8 (n ¼ 17) (C), IL-18 (n ¼ 21) (D),
IL-23 (n ¼ 22) (E) and TGF-b1 (n ¼ 16) (F) were measured by ELISA in tissue-conditioned media from inﬂamed and non-inﬂamed synovium from OA patients. Signiﬁcantly higher
concentrations of all cytokines except IL-23 were measured in media conditioned by inﬂamed OA synovium.
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Fig. 5. Associations between the inﬂammation grade of OA synovial tissues and the concentrations of cytokines measured in synovium-conditioned media. Positive associations
were found between the inﬂammation grade of OA inﬂamed and non-inﬂamed synovial tissues and the concentrations of IL-1b (n ¼ 20) (A), IL-6 (n ¼ 20) (B), IL-8 (n ¼ 20) (C), IL-18
(n ¼ 23) (D), IL-23 (n ¼ 25) (E) and TGF-b1 (n ¼ 20) (F) measured in synovium-conditioned media.
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tissues expressed IL-17 and IL-22 mRNA and released both pro-
teins. A trend toward stronger expression of IL-17 and IL-22 mRNA
was observed in inﬂamed compared with non-inﬂamed tissues
(P ¼ 0.079) [Fig. 6(A) and (B)]. At the protein level, both cytokines
were preferentially released by inﬂamed OA synovium: media
conditioned by inﬂamed, compared with non-inﬂamed tissue,
contained signiﬁcantly higher concentrations of IL-17 and IL-22
[Fig. 6(C) and (D)]. In addition, their release was linked to the in-
ﬂammatory status of the tissues, as suggested by the signiﬁcant
positive correlation observed between MPO and both IL-17
(r ¼ 0.514, P ¼ 0.023) and IL-22 (r ¼ 0.363, P ¼ 0.025) [Fig. 7(A)
and (B) and Supplemental Table]. Nevertheless, we did not observe
any correlation between either IL-17 or IL-22 levels and the in-
ﬂammatory grade of the synovium.
Strong positive correlations were found between the levels of IL-
17 and IL-22 in conditioned media (r ¼ 0.478, P ¼ 0.002) [Fig. 7(C)
and Supplemental Table] and between IL-17 and IL-22 mRNA
expression (r ¼ 0.588, P ¼ 0.022); this ﬁnding suggests an associ-
ation between their expression. Studies of their individual corre-
lations with IL-1b, IL-6, IL-18, IL-23 and TGFb1 found signiﬁcant
positive associations only between levels of IL-23 and both IL-17
and IL-22 levels, and between the levels of TGFb1 and IL-17
(Supplemental Table). In contrast, signiﬁcant correlations were
found between the combined release of IL-6, IL-23 and TGFb1 and
levels of both IL-17 ((r ¼ 0.562, P ¼ 0.0035) and IL-22 (r ¼ 0.434,
P¼ 0.0301) [Fig. 7(C) and (D)]. These results show that IL-17 and IL-
22 were produced by OA synovium and related to synovial
inﬂammation. They also provide evidence that IL-6, IL-23 and
TGFb1 contribute to the release by OA synovium of IL-17 and IL-22.
Discussion
Although OA synovitis is an integral component of OA1,26, we are
far from a clear understanding of either the mechanismsresponsible for its development or its exact contribution to OA
initiation and progression. It is suggested that OA synovitis is
initiated by cartilage degradation products andmediators produced
by chondrocytes1. Recent data also support a role for infrapatellar
fat pad, which speciﬁcally releases factors27e29 able to induce sy-
novial inﬂammation30. Synovitis may favor OA progression via the
release of factors inducing cartilage degradation and synovitis
perpetuation1,31,32.
In contrast to rheumatoid arthritis (RA) synovium, which shows
diffuse inﬂammation, OA synovium appears heterogeneous with
patchy areas of inﬂammation3,22. To understand the molecular and
cellular events responsible for this heterogeneity in OA and the
contribution of synovium in OA progression, it is necessary to study
the inﬂamed and non-inﬂamed areas of OA synovium separately.
Taking advantage of the clear macroscopic differences between
these two types of synovial tissue, as described by Ayral et al.22, we
separated them and analyzed them independently. Our results
showed that this macroscopic discrimination clearly enabled us to
distinguish between inﬂamed and non-inﬂamed areas of the sy-
novial tissues. The ratio of vessel-to-tissue area was signiﬁcantly
greater in inﬂamed tissue, as the hyperemic appearance of those
areas led us to expect. The number of leukocyte clusters was also
signiﬁcantly higher in these tissues and was positively correlated
with the vessel-to-tissue area ratio. Haywood et al.24 previously
reported an association between the endothelial cell fractional area
and the inﬂammation grade.
Moreover, the presence of higher levels of MPO and MMP-9, as
well as of proinﬂammatory cytokines such as IL-1b, IL-6, IL-8 and
IL-18, in inﬂamed, compared with non-inﬂamed areas, points out
the correspondence between the biochemical, histological and
macroscopic characterizations of OA synovium and thus validates
our technique. Accordingly, Lambert et al.4,33, using a similar
approach of macroscopic discrimination between inﬂamed and
normal/reactive OA tissues, recently reported a differential gene
expression pattern between cultured FLS from these two types of
Fig. 6. Differential expression of IL-17 and IL-22 in inﬂamed and non-inﬂamed synovium from OA patients. AeD) Relative quantiﬁcation of IL-17 (A) and IL-22 mRNA expression (B)
in inﬂamed and non-inﬂamed synovium from OA patients (n ¼ 8). mRNA expression was determined by quantitative RT-PCR. The amount of mRNA was normalized against the
amount of GAPDH mRNA measured in the same cDNA. C and D)Measurement of IL-17 (n ¼ 22) (C) and IL-22 (n ¼ 22) (D) levels in tissue-conditioned media from inﬂamed and non-
inﬂamed synovium from OA patients. IL-17 and IL-22 concentrations were signiﬁcantly higher in media conditioned by inﬂamed compared with non-inﬂamed tissues. E) IL-17 and
IL-22 concentrations in media conditioned by OA inﬂamed and non-inﬂamed synovial tissues were strongly and positively correlated.
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overexpressed some inﬂammatory cytokines and angiogenic
factors.
As previously described3,34,35, areas of synovial inﬂammation in
OA were microscopically similar to those seen in RA although the
intensity of inﬂammation was lower. Leukocyte inﬁltration in the
inﬂamed tissues consisted mainly of macrophages and T and B
lymphocytes. Macrophages were localized in the intima and the
subintima, whereas T and B lymphocytes that were organized as
clusters were found only in the subintima. Some neutrophils were
also detected in the subintimal portion of the synovium.
Gelatinases have recently emerged as potential important fac-
tors in OA pathogenesis, through their generation of subchondral
bone resorption and microvascular invasion33,34. In our study, we
clearly observed higher levels of MMP-9 in media conditioned by
tissue from inﬂammatory compared with non-inﬂamed areas.
Many cell types, including the neutrophils present in inﬂamed
areas can release MMP-9. Consistently with previous data
demonstrating that MMP-9 is controlled by various proin-
ﬂammatory mediators, such as IL-1b36, we found a positive corre-
lation between MMP-9 and IL-1b levels.
We clearly demonstrated that IL-17 and IL-22 were both
expressed at higher levels in inﬂamed, compared with non-
inﬂamed, synovium from OA patients. This ﬁnding suggests that
these cytokines may be among the critical mediators of the pro-
cesses implicated in OA pathophysiology. Activated memory CD4þ
Tcells are the primary secretors of IL-17. TGFb1 in combinationwith
IL-6, both found in inﬂamed areas, is known to promote the dif-
ferentiation of Th17 cells37, which in turn secrete IL-17A and IL-22.
IL-23 is an important cytokine required for Th17 cellmaintenance38. In addition, IL-1 and IL-23 synergistically enhanced
the production of IL-22 during Th17 differentiation. Interestingly,
signiﬁcant correlations were found between IL-17 and IL-22 or both
and the combined release of IL-6, IL-23 and TGFb1.
IL-17 is present in synovial ﬂuid from patients with OA8,39, and
the correlation of its concentration with OA disease activity and
MMPexpression in synovialﬁbroblasts suggests that it playsa role in
cartilage destruction40,41. In addition, IL-17 also induces chon-
drocytes and synovial ﬁbroblasts to release proinﬂammatory cyto-
kines such as IL-1, TNF-a, IL-6 and IL-8, which contribute to
inﬂammation, cartilage breakdown and synovial inﬁltration in
OA12,42. Others have demonstrated that IL-17 inhibits proteoglycan
synthesis in rat cartilage43. It also increases the secretion of vascular
endothelial growth factor (VEGF)12 by synovial ﬁbroblasts from OA
patients. VEGF is an up-regulator of angiogenesis, a process that is
stimulated in inﬂamed synovium of OA patients and which con-
tributes to disease progression. IL-17 is known to promote neutro-
phil recruitment and activation. In early RA, the presence of Th17
cells is associated with neutrophil recruitment44. Neutrophils play
an important role in the onset and perpetuation of RA, contributing
to joint erosion by the release of proteolytic enzymes such as MMPs
but also by the production of high quantities of reactive oxygen
species45, especially by MPO. Interestingly, MPO and IL-17 concen-
trations were positively correlated in media conditioned by OA
synovium. The presence of neutrophils in the inﬂamed synovium of
OA patients might thus be involved in OA pathogenesis.
Previous studies indicate that IL-22 may play a pathogenic role
in joint diseases. High levels of IL-22 have been found in the sy-
novial ﬂuid of both psoriatic arthritis (PsA) and RA patients46,47, and
it has been reported to induce signiﬁcant proliferation of FLS in
Fig. 7. The release of IL-17 and IL-22 by OA synovium is linked to MPO levels and is associated with the combined release of IL-6, IL-23 and TGF-b1. A and B) Correlations of IL-17
(n ¼ 38) (A) and IL-22 release (n ¼ 39) (B) by OA inﬂamed and non-inﬂamed synoviumwith the release of MPO. C and D) Analysis of the combined release of IL-6, IL-23 and TGF-b1
by OA inﬂamed and non-inﬂamed synovium according to the release of IL-17 (n ¼ 28) (C) and IL-22 (n ¼ 26) (D). The secretion of IL-6, IL-17, IL-22, IL-23 and TGF-b1 was ranked for
all tissues analyzed, and the mean rank of IL-6, IL-23 and TGF-b1, which corresponded to their combined release by each inﬂamed and non-inﬂamed tissue, was calculated. Data are
expressed as the secretion rank of IL-17 or IL-22 according to the rank of combined release of IL-6, IL-23 and TGF-b1.
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to wild-type mice, tend to be less susceptible to collagen-induced
arthritis with lower levels of visible (swelling, redness) and histo-
logic (pannus formation, bone destruction) joint pathology, as well
as decreased synovial expression of IL-1b, IL-6, TNF-a and MMP-
949. IL-22 expression has previously been shown in the synovium of
RA patients48,50. The pathogenic role of IL-22 in this model was
inferred by the authors because this cytokine increased osteoclas-
togenesis in vitro, a process that might be related at least in part to
the induction of RANKL in synovial ﬁbroblasts47. IL-22 levels in
synovial ﬂuid are signiﬁcantly lower in OA patients than in people
with PsA and RA. Furthermore, activated synovial T cells from OA
patients produce signiﬁcantly lower levels of IL-22 than those from
PsA and RA patients15. A recent study nonetheless reported that IL-
22 and IL-22R1 are constitutively expressed in FLS fromOA patients
and that IL-22 enhances FLS proliferation and upregulates the
expression of MMP, as well as alarmins, which are mediators
involved in regulation of the cytoskeleton, cell migration and
inﬂammation21.
The release of IL-17 and IL-22 is linked to the inﬂammatory
status of the synovium, as suggested by the signiﬁcant positive
correlation observed between MPO and both IL-17 and IL-22.
However, we did not ﬁnd any correlation between the expression
of these cytokines and histological grade. The effect of IL-22 and IL-
17 likely depends on the stage of synovial inﬂammation: previous
studies of RA have reported IL-22-induced osteoclastogenesis in the
later phases of the disease47, and a recent work describes the
contribution of IL-22 in the later phase of inﬂammation51. In
contrast, IL-17 plays a critical role in the initial phase of RA44.This study includes some limitations. It is a descriptive study
focusing on the characterization of OA synovitis without any data
on the functional importance of synovitis in OA. No control tissue,
including synovium from healthy and inﬂamed disease donors, was
studied in parallel to OA synovium. In the literature, “healthy”
synovium are obtained from symptomatic patients who suffer from
traumatic knee lesions. These donors are younger than OA patients
operated for total knee arthroplasty, young and aged tissues dis-
playing different characteristics in term of cell to matrix content, of
cell metabolism and production of inﬂammatory mediators52,53.
We separated inﬂamed and non-inﬂamed areas based on the hy-
peremic appearance of the inﬂamed areas as described by Ayral
et al.22. There was an obvious heterogeneity in the inﬂammatory
degree of the synovium between patients. Samples for some pa-
tients contained only inﬂamed or non-inﬂamed tissues. It could be
due either to the size of the samples, which varied upon donors and
did not include all the synovium, or to different pathological
mechanisms leading to OA from one patient to the other54. Further
studies are necessary to investigate the inﬂammatory status of the
synovium upon the etiology of OA. This heterogeneity in the in-
ﬂammatory degree of the synovium between patients implies that
the inﬂamed area of some patients could be similar to the non-
inﬂamed area of other ones. Moreover, some non-inﬂamed and
inﬂamed areas from different synovium were graded as two in the
histological evaluation of the synovium established by Haywood
et al.24. The partial overlap in cytokine concentrations of inﬂamed
and non-inﬂamed tissue-conditioned media also reﬂects this
phenomenon. This underlines the variable intensity of synovitis in
OA, as shown by correlations between cytokine levels released by
C. Deligne et al. / Osteoarthritis and Cartilage 23 (2015) 1843e1852 1851OA synovium and the inﬂammation grade of the tissues. To better
characterize this point, it would be informative to study the link
between the cytokine levels and the inﬁltration of the different
types of leukocyte into OA synovium. Despite its efﬁcacy, this
macroscopic evaluation is therefore a relative discrimination be-
tween two apparent different areas and can only be considered in
studies where a paired analysis is performed.
In conclusion, inﬂamed areas of synovium in OA secrete a wide
range of cytokines, including IL-17 and IL-22. This study suggests
for the ﬁrst time that IL-22 plays a key role in synovitis in OA
patients.
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